| Document |
Document Title |
|
WO/2006/098394A1 |
The invention relates to a method for inhibiting lipid absorption from the small intestine comprising administering a compound having a CETP inhibitory effect to a subject to be administered and an inhibitor of lipid absorption from the ...
|
|
WO/2006/095771A1 |
Disclosed is a novel gadolinium complex compound exhibiting responsiveness to compounds and ions other than zinc ion. Also disclosed is an MRI probe made of such a gadolinium complex compound. Specifically disclosed is a gadolinium compl...
|
|
WO/2006/093864A1 |
The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide ...
|
|
WO/2006/087135A1 |
The invention relates to compositions containing at least one tetrazine derivative of general formula (I), wherein the radicals R1 to R8 independently represent a hydrogen atom or an optionally substituted alkyl radical, alkenyl radical,...
|
|
WO/2006/085111A1 |
Therapeutically active anthranilic acid derivatives of Formula (I) or of Formula (Ia) wherein R, R1, R2 and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing ...
|
|
WO/2006/085510A1 |
A remedy for IBS comprising, as the active ingredient, a dual antagonist for 5-HT2B and 5-HT7 receptors which shows selective binding affinities to 5-HT2B and 5-HT7 receptors. The above-described medicinal composition is superior in the ...
|
|
WO/2006/081807A2 |
The invention relates to a novel method for the production of losartan, an imidazol derivative with the chemical name 2-n-butyl-4-chloro-5-hydroxymethyl-1-{[2'-(1H-tetrazol-5-yl)
biphenyl-4-]methyl}imidazol and the pharmacologically acti...
|
|
WO/2006/079610A1 |
Angiotensin II receptor blockers nitroderivatives of Formula (I) having wider pharmacological activity and enhanced tolerability. They can be employed for treatment cardiovascular and renal diseases and inflammatory processes.
|
|
WO/2006/076561A1 |
The present invention provides a process for the preparation of amorphous valsartan.
|
|
WO/2006/074244A2 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
|
WO/2006/067216A2 |
It comprises new substituted 4-valinylmethylphenyl boronic acids of formula (II) and their derivatives and also its preparation process. It also comprises a preparation process of Valsartan (I) from such intermediates. The process compri...
|
|
WO/2006/067139A1 |
The present invention concerns substituted triazolone, tetrazolone and imidazolone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereo...
|
|
WO/2006/064179A1 |
There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): whe...
|
|
WO/2006/061706A1 |
This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination conta...
|
|
WO/2006/062093A1 |
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...
|
|
WO/2006/059245A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, ...
|
|
WO/2006/058701A1 |
This invention relates to an improved process for preparing a valsartan, or a pharmaceutically acceptable salt thereof, or pharmaceutical preparation containing either entity wherein a compound of formula (II) 'Formula (II)' or a salt th...
|
|
WO/2006/056854A1 |
Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain oth...
|
|
WO/2006/057870A1 |
The present invention provides compounds of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.
|
|
WO/2006/057869A1 |
The present invention provides a compound of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes for preparing the same, and intermediates thereof.
|
|
WO/2006/057860A1 |
The present invention provides compounds of formula (I); pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.
|
|
WO/2006/055187A1 |
Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
|
|
WO/2006/051751A1 |
Provided is a method for preparing 2-alkoxy-5-tetrazolyl-benzaldehyde compound with safety and with good efficiency, through the formylation of a (4-alkoxyphenyl)-tetrazol compound. A method for preparing 2-alkoxy-5-(alkyltetrazol-5-yl)-...
|
|
WO/2006/051142A1 |
The invention relates to macrocyclic compounds having general formula A and the paramagnetic complexes of lanthanides thereof which are used as contrast agents for magnetic resonance imaging. More specifically, the invention relates to c...
|
|
WO/2006/046593A1 |
Disclosed is an excellent LXR modulator. Specifically disclosed is a compound represented by the general formula (I) below or the like. (I) [In the formula, R1 represents a -COR9 (wherein R9 represents an alkyl, optionally substituted al...
|
|
WO/2006/046980A1 |
An organic light emitting device is provided. The device has an anode, a cathode and an organic layer disposed between the anode and the cathode. The organic layer comprises a compound further comprising one or more arylpyrazole, arylimi...
|
|
WO2005030705A9 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2006/038606A1 |
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...
|
|
WO/2006/035157A2 |
The invention relates to poly-substituted N-(benzyl)phenylacetamide-type derivatives having formula (I), pharmaceutical compositions containing same and the therapeutic use thereof as PPAR ligands, such as in the human and animal health ...
|
|
WO/2006/029193A2 |
The present invention is directed to the field of substituted tetrazole synthesis and manufacture. More particularly, the present invention is directed to processes for preparing substituted tetrazoles and tetrazolate salts, such as sodi...
|
|
WO/2006/018872A1 |
An additive for copper plating, comprising a specified nitrided biphenyl derivative as an active ingredient; a copper plating solution containing a copper ion component and an anion component, obtained by addition of this additive for co...
|
|
WO/2006/015158A1 |
The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders assoc...
|
|
WO/2006/012996A1 |
The invention relates to compounds of formula (I) wherein R1 represents hydrogen or respectively optionally substituted alkyl, alkenyl, alkinyl or phenyl, said compounds being highly suitable as microbicides for protecting plants and mat...
|
|
WO/2006/015134A1 |
A process for preparing candesartan cilexetil.
|
|
WO/2006/013042A2 |
New compounds of the general formula: Xm-G-Cln are described as well as methods for their production. These constitute multivalent chelator-compounds with an affinity-tag binding to metal-chelator-complexes which can selectively modify a...
|
|
WO/2006/002873A2 |
The present invention relates to a novel class of ligands for use in paramagnetic ion-based contrast agents of formula e (III) or (IIIa) wherein: R is, independently, H or a C2-C70 aminopolyol moiety comprising a straight or branched alk...
|
|
WO/2006/002875A1 |
The present invention relates to a novel class of paramagnetic ion-based contrast i agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhdroxylated chain, that show a pha...
|
|
WO/2006/002874A1 |
The present inyention relates, to a novel class of paramagnetic ion-based contrast agents of formulae (IV) and (V), wherein a chelating backbone moiety is highly functionalized by the presence of one or more- polyhydroxylated chain, that...
|
|
WO/2005/123700A1 |
The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atheroscleros...
|
|
WO/2005/121109A2 |
A compound of Formulae (1), (2) or (3), A1-Ph (1) or A1-Ar-A2 (2) or A1-(A2)A’-A3 (3) wherein A1, A2 and A3 are selected from Formulae (4), (5) and (6), or a salt whereof; wherein Ar is selected from the group consisting of 1,2-phenyl,...
|
|
WO/2005/118715A2 |
A vinylated tetrazole substituted at the 5-position of the tetrazole ring is formed by a water-based method. A gas generating composition 12 containing the vinylated tetrazole is contained within an exemplary gas generator 10. A gas gene...
|
|
WO/2005/118575A1 |
The invention relates to compounds of formula (I) wherein Ar, X, R1, R2, R3 and R4 are as defined herein and pharmaceutical compositions thereof useful, either alone or in combination with other therapeutic agents as reverse transcriptas...
|
|
WO/2005/116010A1 |
This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressur...
|
|
WO/2005/115997A1 |
Metal complexes of general formula (I), where Hal = bromine or iodine and A1 and A2 have differing meanings are suitable as contrast agents.
|
|
WO/2005/113518A1 |
A process for preparing irbesartan comprises pentanoylation of cycloleucine in the presence of sodium hydroxide to form n-pentanoyl cycloleucine, condensing this product with 2-(4-aminomethyl phenyl) benzonitrile using dicyclohexyl carbo...
|
|
WO/2005/113513A2 |
The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.
|
|
WO/2005/111003A1 |
A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modul...
|
|
WO/2005/108368A1 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
|
WO/2005/108379A1 |
The invention relates to metal complexes of general formula (I), wherein Hal is bromine or iodine and A1 and A2 have different significances and said complexes are suitable in the form of contrast agents.
|
|
WO/2005/105770A2 |
The present invention relates in part to compounds of formulas I and III: and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The prese...
|
